Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).

NCT06175351 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG: 9MW1911
DRUG: Placebo

Sponsor

Mabwell (Shanghai) Bioscience Co., Ltd.